Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 147   

Articles published

BMY 50.73 -0.22 (-0.43%)
price chart
Bristol-Myers Squibb Co (NYSE:BMY): Strengthen Manufacturing Capability
Boston, MA 04/24/2014 (wallstreetpr) - Bristol-Myers Squibb Co (NYSE:BMY) and Samsung BioLogics have extended their manufacturing agreement to develop and produce biologic medicines for Bristol-Myers.
Bristol-Myers Squibb Ranks First on 2014 Best Corporate Citizens List  Wall Street Journal
Bristol-Myers Squibb Rating Increased to Neutral at Ned Davis Research (BMY)  Watch List News (press release)
Related articles »  
Bristol-Myers Squibb: Great Dividend Stocks From The Bond Refugee Screen ...
BMY continues to focus research and development in the areas highlighted below while evolving to a bio pharmaceutical company. (click to enlarge). Valuation. BMY has an $84.2 billion market capitalization and enterprise value of $84.5 Billion. BMY ...
Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement
Bristol-Myers Squibb Company (NYSE:BMY) and Samsung BioLogics today announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for ...
Bristol-Myers Squibb Co (NYSE:BMY) Unveils A New Combination To Fight HIV
Boston, MA 04/17/2014 (wallstreetpr) - Bristol-Myers Squibb Co (NYSE:BMY) said that it has filed a new drug application (NDA) with the U.S.
News Buzz-Aetna Inc (NYSE:AET), Bristol-Myers Squibb Co (NYSE:BMY ...  Techsonian (press release)
Hot Healthcare Movers: UnitedHealth Group (NYSE:UNH), Teva Pharmaceutical ...  Gaining Green
Related articles »  
Bristol-Myers Squibb Upgraded to ´┐ŻNeutral´┐Ż at Ned Davis Research (BMY)
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences ...
While leader Gilead Sciences (NASDAQ: GILD ) waits on the FDA review for its combination of Sovaldi and levipasvir, and battles questions over Sovaldi's price tag, Merck is producing data on easy-to-treat populations and Bristol-Myers Squibb has turned ...
Related articles »  
Bristol-Myers Squibb to Announce Results for First Quarter 2014 on April 29
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2014 on Tuesday, April 29, 2014. During a conference call at 9 a.m.
Related articles »  
Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA ...
PRINCETON, N.J., Apr 07, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have submitted new drug applications (NDAs) with the U.S.
Related articles »  
Technical Pointers on Pharmaceuticals Equities -- Research on Merck, Bristol ...
Sign up today to read free research on MRK at: http://www.investor-edge.com/843-MRK-07Apr2014.pdf Shares in Bristol-Myers Squibb Co. witnessed a trading volume of 8.44 million shares on Friday, as compared with its three months average volume of ...
Related articles »  
Ex-Dividend Reminder: Bristol-Myers Squibb, DCT Industrial Trust and Aviva
Looking at the universe of stocks we cover at Dividend Channel, on 4/2/14, Bristol-Myers Squibb Co. (NYSE: BMY), DCT Industrial Trust Inc (NYSE: DCT), and Aviva plc (NYSE: AV) will all trade ex-dividend for their respective upcoming dividends.